Posted in | News | Nanoanalysis

Waters Introduces New System to Automate Liquid Chromatography Method

Waters Corporation (NYSE: WAT) today unveiled its new Waters® ACQUITY UPLC® H-Class Method Development System that automates liquid chromatography method development according to Quality-by-Design (QbD) guidelines to produce robust, fit-for-purpose methods in dramatically less time than traditional processes.

The superior performance of the new system stems from the power and integration of four class-leading components: ACQUITY UPLC H-Class; Fusion Method Development™ Software; Empower™ 2 Chromatography Data Software, and; Waters Method Development Chemistry Kits.

"The ACQUITY UPLC H-Class Method Development System combines industry-leading separation capabilities with cutting-edge, automated software and data management to consistently produce rugged, robust LC methods in a fraction of the time," said Warren Potts, Pharmaceutical Business Director for the Waters Division.  "The chromatographic flexibility and power of Waters' recently introduced ACQUITY UPLC H-Class system is transforming modern method development as laboratories continue to adopt new UPLC methods and transfer older HPLC methods to UPLC. Now the integration of Fusion Software (S-Matrix Corporation) with ACQUITY UPLC H-Class has taken automated method development to entirely new levels of efficiency and productivity, thereby reducing costs and decreasing time-to-market."

The key to the ACQUITY UPLC H-Class Method Development System is its use of QbD-based methodology for LC method development, allowing scientists to develop the best possible method much faster and with greater confidence. Fusion works with Empower 2 and ACQUITY UPLC to increase lab efficiency by designing statistically-valid experiments and automatically reconstructing them in Empower 2 as fully ready-to-run sequences. Fusion uses the resulting data to generate parameter-effects models which establish the final design and operating spaces for truly optimized LC methods. With new features introduced on the ACQUITY UPLC H-Class such as multi-solvent blending, versatile column management options, and reliable Method Development Kits available in a variety of chemistries, the ACQUITY UPLC H-Class Method Development System's capabilities to ensure a quality method is developed the first time is unmatched.

To benchmark the effectiveness of Fusion Method Development Software used in combination with Empower 2 and ACQUITY UPLC, a large pharmaceutical company demonstrated that it was possible to reduce method development time for a complex drug product from 45-60 days to two days when compared to the conventional one-factor-at-a-time development approach.

The ACQUITY UPLC H-Class Method Development System also addresses regulatory recommendations to incorporate robustness into LC method development (ICH Q2B Validation of Analytical Procedures – Methodology). Utilizing a patented approach built on sound statistical process control techniques, the Fusion Software computes and models the impact of key chromatographic parameters on method robustness. This enables identification of methods optimized for both mean performance and robustness without the need for any additional experiments. Establishing the final design space for a method in this manner creates the basis for flexibility and continuous improvement (ICH Q8(R2) Pharmaceutical Development).

Pharmaceutical organizations can standardize their approach to LC with this common technology platform that makes the future transition from HPLC to efficient UPLC-based methods straightforward and practical - from discovery through to product release testing. With additional tools such as Method Transfer and Method Validation Kits, seamless transfer from an HPLC to a UPLC, or vice versa, is ensured.

Source: http://www.waters.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.